These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1697503)

  • 1. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
    Toner GC; Geller NL; Tan C; Nisselbaum J; Bosl GJ
    Cancer Res; 1990 Sep; 50(18):5904-10. PubMed ID: 1697503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
    Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors?
    Gerl A; Lamerz R; Mann K; Clemm C; Wilmanns W
    Anticancer Res; 1997; 17(4B):3047-9. PubMed ID: 9329598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
    Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
    Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors.
    Kim A; Ji L; Balmaceda C; Diez B; Kellie SJ; Dunkel IJ; Gardner SL; Sposto R; Finlay JL
    Pediatr Blood Cancer; 2008 Dec; 51(6):768-73. PubMed ID: 18802946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of human chorionic gonadotropin and alpha-fetoprotein radioimmunoassays: specificity and apparent half-life determination after delivery and in patients with germ cell tumors.
    Mann K; Lamerz R; Hellmann T; Kümper HJ; Staehler G; Karl HJ
    Oncodev Biol Med; 1980; 1(4-5):301-12. PubMed ID: 6169065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
    Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
    J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
    Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
    J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.
    Vogelzang NJ; Lange PH; Goldman A; Vessela RH; Fraley EE; Kennedy BJ
    Cancer Res; 1982 Nov; 42(11):4855-61. PubMed ID: 6181870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
    Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
    Oncodev Biol Med; 1981; 2(1-2):129-34. PubMed ID: 6170953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
    Christensen TB; Engbaek F; Marqversen J; Nielsen SI; Kamby C; von der Maase H
    Br J Cancer; 1999 Jul; 80(10):1577-81. PubMed ID: 10408402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
    J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
    Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
    J Clin Oncol; 2005 Sep; 23(25):6149-56. PubMed ID: 16135481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression pattern of alpha fetoprotein level changed after treatment of malignant germ cell tumor.
    Sanersak S; Prueksritanond N
    J Med Assoc Thai; 2008 Mar; 91(3):287-94. PubMed ID: 18575279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in metastatic nonseminomatous germ cell tumours.
    Hanson PR; Belitsky P; Millard OH; Lannon SG
    Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary mediastinal nonseminomatous germ cell tumors. Results of a multimodality approach.
    Wright CD; Kesler KA; Nichols CR; Mahomed Y; Einhorn LH; Miller ME; Brown JW
    J Thorac Cardiovasc Surg; 1990 Feb; 99(2):210-7. PubMed ID: 2153877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of tumor markers in the treatment of germ cell tumor].
    Niwakawa M; Tobisu K
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
    Keskin S; Ekenel M; Başaran M; Bavbek S
    Am J Clin Oncol; 2012 Aug; 35(4):369-72. PubMed ID: 22814307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.